Tools for studying epigenetic markers in cancer
We collaborate with key opinion leaders in oncology and epigenetics to develop high-quality and reliable products that advance your understanding of cancer epigenetics. The study of epigenetic markers is critical for developing novel therapeutic approaches in cancer research and treatment.
Explore our curated portfolio of gold-standard antibodies, knock-out cell lines and immunoassays, including our 90-minute SimpleStep ELISA® kits.
Recombinant antibodies: key targets
Accelerate your research with our premium recombinant antibodies, engineered for sensitivity, specificity and reproducibility. Our unbeatable range covers all established and emerging targets for research in acute myeloid leukemia (AML), melanoma, non-small cell lung cancer (NSCLC) and breast cancer.
We’re serious about the quality of our antibodies, which is why we subject them to industry-leading validation. We undertake extensive application testing, including in IHC, WB, ICC/IF and flow cytometry, as well as applications supporting NGS like CUT&RUN and ChIP-seq.
Browse our curated catalog of gold-standard antibodies to find the right tools to study the complex interplay between epigenetic modifications and cancer.
Product highlights
Anti-METTL3 antibody [EPR18810]
- Top-cited antibody for this target with over 400 citations
- Six 5* reviews
- Validated in IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P; reacts with human, mouse and rat samples
- Knock-out validated
Anti-BRG1 antibody [EPNCIR111A]
- Top-cited antibody for this target with over 200 citations
- Five 5* reviews
- Validated in ChIC/CUT&RUN-seq, IHC-P, IP, WB, ICC/IF, Flow Cyt (Intra); reacts with human, mouse and rat samples
- Knock-out validated
- Optimized for the Leica® BOND™ system
Anti-KMT6 / EZH2 antibody [EPR25353-284]
- Validated in ChIP, IP, Flow Cyt (Intra), ICC/IF, IHC-P, WB, ChIC/CUT&RUN-seq; reacts with human, mouse and rat samples
- Knock-out validated
- Optimized for the Leica® BOND™ system
Leica® is a registered trademark of Leica Microsystems IR GmbH. BOND™ is a trademark of Leica Biosystems Melbourne Pty. Ltd
Recombinant antibodies: histone modifications
Our histone modification antibodies specifically recognize and bind to modified histones, making them a critical tool in your research. Our antibodies enable you to identify regions of the genome associated with active or repressive chromatin states, crucial for your study of the role of epigenetic changes in cancer.
To ensure effectiveness, we validate our recombinant antibodies using ChIP or CUT&RUN, followed by next-generation sequencing (NGS). Our histone post-transcriptional modification antibodies are also validated using peptide arrays, giving you improved specificity and enhanced reliability. This advanced validation program demonstrates specificity to de-risk your antibody selection process, giving you confidence in your results.
Product highlights
Anti-Histone H3 (acetyl K27) antibody [EP16602] - ChIP Grade
- Over 100 citations
- Seven 5* reviews
- Validated in ICC/IF, ChIP, WB, PepArr, Flow Cyt (Intra) and IHC-P, as well as applications supporting NGS like ChIP-seq, ChIC/CUT&RUN-seq
- Reacts with human, mouse and rat samples
- Optimized for the Leica® BOND™ system
Anti-Histone H3 (tri methyl K27) antibody [EPR18607] - ChIP Grade
- ~100 citations
- Six 5* reviews
- Validated in ChIP, ELISA, WB, PepArr, ICC/IF, ChIP-seq, IHC-P; reacts with human, mouse and rat samples
Leica® is a registered trademark of Leica Microsystems IR GmbH. BOND™ is a trademark of Leica Biosystems Melbourne Pty. Ltd
SimpleStep ELISA® kits
Our SimpleStep ELISA® kits deliver ultimate speed and flexibility without compromising on performance. Thanks to their one-wash protocol, our SimpleStep ELISA® kits yield results in just 90 minutes. Our kits are powered by our precision recombinant antibodies, giving you the sensitivity, specificity and reproducibility your research deserves.
Our broad range of kits covers key targets in cancers such as acute myeloid leukemia (AML), melanoma, breast cancer and non-small cell lung cancer (NSCLC). We validate our kits in multiple sample types, like serum, plasma, cell culture supernatants and tissue extracts so you can choose the right kit for you with confidence.
We now offer a growing range of kits available in a 384-well format. These kits have exactly the same simple protocol as our standard 96-well kit but use only a quarter of the sample volume so you can get the most data possible from your precious samples.
Product highlights
Human Flt-3 ligand ELISA Kit
- Detection at 2 pg/mL sensitivity
- Validated in human plasma, serum and cell culture supernatants
- 384-well format available
Human CDKN2A/p16INK4a ELISA Kit
- Detection at 1.3 ng/mL sensitivity
- Validated in human cell culture and tissue extract samples
Knock-out cell lines
Streamline your experimental process and get back to generating data with our broad range of premium knock-out cell lines. We tailor our cell lines for specific cancer types, providing you with robust models for gene function study and targeted therapy development. We validate our cell lines in a broad range of applications, including ICC, NGS, WB, ELISA and flow cytometry.
Product highlights
Human IL13RA2 knockout A375 cell line
- KO validated by ICC, NGS and WB
- Also validated in U-87-MG and Daudi cell lysates
- A375 is a melanoma cell line, making this a robust model for gene function study
Human BSG (CD147) knockout A549 cell line
- KO validated by Sanger sequencing, WB, Flow Cyt and ELISA
- Also validated in Raji and Jurkat cells
- A549 is a human lung adenocarcinoma cell line, making this a robust model for gene function study
